What XCancer Research does

XCancer Research is a privately-held clinical research and services consortium headquartered in Omaha, Nebraska, focused on oncology theranostics—the pairing of diagnostic imaging with targeted radiopharmaceutical therapy for personalized cancer treatment. The flagship operating asset is the XCancer Omaha clinic, founded in 2010 by Dr. Luke Nordquist, which has become a globally recognized destination for prostate cancer care and research, treating more than 450 patients per month drawn from over 40 U.S. states and multiple countries, and contributing to 20+ First-in-World clinical advancements including landmark work in Ga-68 PSMA PET imaging and Lu-177 PSMA therapy.

The consortium architecture comprises nine operating divisions spanning clinical care (XCancer Omaha), clinical trial conduct (XCancer Research Network), proprietary trial software (XCancerSuite), a global trial information and education platform (TheranosticTrials.org), sponsor-facing consulting (XCancer Consulting), radiation safety and regulatory services (XCancer Health Physics Services), a nonprofit foundation with international reach (XCancer Foundation), a merchandise storefront (XCancer Store), and an awareness initiative via motorsport racing (XCancer Motorsports). Technology is organized around two core digital assets: XCancerSuite, which enables rapid trial activation and data management at community cancer centers, and TheranosticTrials.org, a centralized hub with real-time statistics and educational resources covering every theranostic clinical trial globally. The Health Physics Services unit adds regulatory and radiation safety consulting with 30+ years of nuclear medicine expertise.

Revenue is generated primarily through professional services: per-patient clinical trial participation fees (including Phase II–III registrational trials such as the Phase III AMPLIFY trial with Clarity Pharmaceuticals), consulting engagements with pharmaceutical sponsors, CROs, and biotech innovators, regulatory/safety consulting for radiopharmaceutical programs, and ancillary merchandise revenue flowing through the foundation. The go-to-market model is hybrid and channeled through three vectors: (1) enterprise-level relationships with pharmaceutical sponsors and CROs for trial conduct and consulting, (2) direct patient care at the Omaha flagship, and (3) a national community oncology network that enables trial decentralization across the U.S. Customer concentration is split among individual prostate cancer patients, pharmaceutical/biotech trial sponsors, and community cancer centers as network participants. The company is founder-led by Dr. Luke Nordquist (CEO), with no disclosed external venture or private equity backing.

Name

XCancer Research

Legal name

XCancer

Website

https://xcancer.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

XCancer Research is a private, founder-led clinical research consortium in Omaha that conducts oncology theranostic trials, operates a destination prostate cancer clinic, runs a community cancer center network, and sells proprietary trial software and consulting to pharma sponsors.

Ownership category

akta.pro rank

Product category

Oncology Clinical Research Services

NAICS

Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Oncology Telemedicine Platforms (HLALAGAH)

Keywords

• Oncology clinical trials
• Radiopharmaceutical research
• Theranostic drug development
• Prostate cancer care
• Clinical trial management

Headquarters

HQ city

Omaha

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Services: XCancer provides clinical trial conduct services through its Omaha clinic and research network, participating in Phase II-III registrational trials for radiopharmaceutical companies.
2. XCancer Consulting: Consulting services offered to pharmaceutical sponsors, CROs, and biotech innovators for designing, scaling, and executing prostate cancer and theranostic programs. Led by Dr. Luke Nordquist with over 50 radiopharmaceutical trials led experience.
3. XCancer Foundation & Merchandise: XCancer Store sells merchandise with proceeds supporting the XCancer Foundation's mission to expand access to life-saving cancer innovations globally.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

XCancer is a consortium of companies that conducts oncology clinical trials and provides site management, patient enrollment, regulatory oversight, and data management services for radiopharmaceutical and theranostic therapies. Its offerings span direct prostate cancer patient care at the flagship Omaha clinic, expert consulting for pharmaceutical sponsors and CROs, a national network empowering community cancer centers to run trials, radiation safety/health physics consulting, and proprietary digital platforms (XCancerSuite for trial activation and TheranosticTrials.org for theranostic trial discovery).

Product overview

XCancer is a consortium of leading-edge companies united by a singular mission to fight cancer through Expanding the Reach of Cancer Innovations. The organization operates as a platform-plus-modules architecture centered around XCancerSuite (a proprietary software platform enabling rapid trial activation and data management) and TheranosticTrials.org (a global search engine for radiopharmaceutical clinical trials). These core digital platforms are complemented by clinical services including XCancer Omaha (a globally recognized prostate cancer treatment center), XCancer Consulting (expert consulting for pharmaceutical sponsors and CROs), and the XCancer Research Network (empowering community cancer centers to conduct cutting-edge trials). Additional supporting services include XCancer Health Physics Services (radiation safety consulting), XCancer Foundation (nonprofit for global access), XCancer Store (merchandise supporting the foundation), and XCancer Motorsports (awareness initiative through racing).

Differentiator

Problem solved

Functional benefit

Brands

• TheranosticTrials.Org: World's leading platform for comprehensive access to cancer theranostic clinical trials, serving as a centralized hub connecting researchers, clinicians, industry partners, patients, and advocates across the global theranostics ecosystem
• XCancer Consulting
• XCancer Research Network
• XCancer Foundation
• XCancer Store
• XCancer Software
• XCancer Health Physics Services
• XCancer Motorsports

Products and services

• XCancer Omaha Clinic Direct clinical services for prostate cancer patients including diagnostic imaging, radiopharmaceutical therapy (e.g., Lu-177 PSMA), and access to First-in-World clinical trials at the flagship Omaha, Nebraska clinic.
• XCancer Consulting Expert consulting services led by Dr. Luke Nordquist for pharmaceutical sponsors, CROs, and biotech innovators on designing, scaling, and executing prostate cancer and theranostic/radiopharmaceutical clinical trial programs, with insight into community oncology and patient accrual.
• XCancer Research Network Clinical trials network enabling community cancer centers across the United States to participate in cutting-edge oncology trials, providing trial identification, regulatory oversight, data management, contracts, finances, operations, and strategic guidance to launch trials within weeks.
• XCancer Health Physics Services Radiation safety and regulatory consulting for facilities developing or expanding radiopharmaceutical programs, including radiation protection program development, shielding evaluations, licensing assistance, equipment testing, and training.
• TheranosticTrials.org Centralized global platform providing comprehensive access to cancer theranostic clinical trial information, real-time statistics, and educational resources for researchers, clinicians, industry partners, patients, and advocates across the theranostics ecosystem.

Quantifiable outcome

• 450+ patients served monthly at single Omaha location
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Facet Life SciencescoreStrategic or Co-development Partner · 6 November 2025Strategic partnership announced November 6, 2025 between Facet Life Sciences (a leader in regulatory strategy and drug development services) and XCancer (global leader in theranostic clinical research) to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.
• Clarity PharmaceuticalscoreStrategic or Co-development Partner · 29 May 2025Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on developing next-generation cancer treatments, partnered with XCancer for its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. XCancer Omaha successfully imaged the first patient in May 2025.
• DEForce RacingminorGTM or Marketing PartnerXCancer Motorsports is backed by DEForce Racing. The racing team competes in the USF Pro Championship Series, a pivotal step on the Road to Indy, raising awareness and support for cancer research through motorsport events.
• Oncidium FoundationminorGTM or Marketing PartnerDr. Luke Nordquist appeared on the Oncidium Foundation Podcast discussing theranostics access and his referral guide for prostate cancer, contributing to patient education and awareness.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: IQVIA is the world's largest contract research organization, offering full-service clinical trial operations, site networks, and consulting. XCancer Consulting and XCancer Research Network compete for a portion of the same sponsor outsourcing budget that IQVIA captures, particularly for community oncology and radiopharmaceutical program design.
• Foundation Medicine: Foundation Medicine, a subsidiary of Roche, provides comprehensive genomic profiling and connects patients to precision oncology trials. It is comparable to XCancer in using data platforms to bridge sponsors, clinicians, and patients in oncology trial access, though at much larger scale and with a broader (not theranostic-specific) indication focus.
• ICON plc: ICON is a major global CRO with deep oncology and radiopharmaceutical trial capabilities acquired through PRA Health and other deals. It competes with XCancer's consulting and site-management offerings for enterprise oncology trial outsourcing engagements.

Others

• Lantheus Holdings: Lantheus is a radiopharmaceutical company with approved diagnostic and therapeutic agents (e.g., PYLARIFY for PSMA PET). As a likely sponsor of theranostic trials using XCancer-like sites, it is a relevant ecosystem participant and a potential enterprise customer for XCancer Consulting and XCancer Research Network.
• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with approved PSMA imaging agents and an expanding theranostic pipeline. It is a probable future sponsor of community oncology trials and a natural counterpart to XCancer's specialized site and consulting services in the theranostics ecosystem.
• Clarity Pharmaceuticals: Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation PSMA-targeted agents including 64Cu-SAR-bisPSMA. It is a current XCancer partner/customer (Phase III AMPLIFY trial) and a leading indicator of sponsor demand for theranostic-focused sites, making it a key ecosystem participant rather than a direct competitor.

Direct peers

• Sarah Cannon Research Institute: Sarah Cannon is one of the largest community oncology site networks in the US, conducting Phase I-III clinical trials across a wide range of cancer types. It directly parallels XCancer Research Network's model of enabling community cancer centers to participate in cutting-edge trials through centralized operational support.
• US Oncology Research: US Oncology Research operates a large network of community-based oncology sites that enroll patients into sponsored clinical trials. Like XCancer Research Network, it provides the regulatory, data management, and operational backbone that allows community centers to run enterprise-grade trials, and serves the same pharmaceutical sponsor buyer.
• START (South Texas Accelerated Research Therapeutics): START is a global network of early-phase oncology clinical trial sites, with deep expertise in radiopharmaceutical and theranostic trials. It is directly comparable to XCancer Omaha's specialized radiopharmaceutical trial capabilities and serves the same sponsor/CRO buyer seeking high-accrual, expert oncology sites.

Emerging players

• Tempus AI: Tempus combines molecular profiling, data, and a clinical trial matching platform (Tempus One) for oncology. Its trial-matching and precision medicine infrastructure overlaps with TheranosticTrials.org and XCancerSuite, and it competes for the same sponsor attention in radiopharmaceutical/precision oncology program design.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/UrologyCancerCenterandGUResearchNetwork
• LinkedInlinkedin.com/company/28655408/admin

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XCancer Research